Bcr-Abl (inhibitors, antagonists, agonists)-ProbeChem.com

Request The Product List ofBcr-Abl Bcr-Abl

Bcr-Abl tyrosine kinase (Breakpoint cluster region Abelson) is a constitutively activated cytoplasmic tyrosine kinase (TK) and is the underlying cause of chronic myeloid leukemia (CML). To date, imatinib represents the frontline treatment for CML therapy. The development of resistance has prompted the search for novel Bcr-Abl inhibitors.

In Philadelphia chromosome-positive (Ph⁺) acute lymphoblastic leukemia (ALL), the BCR-ABL translocation is the main transforming event; consequently, it is targeted by ABL-tyrosine kinase inhibitors (TKIs), the first of which to be identified was imatinib mesylate. There are now four newer TKIs, three so-called second-generation inhibitors and one third generation inhibitor, all of which are more potent than imatinib in in vitro assays. Since 2001, the Bcr-Abl inhibitor imatinib represents the first-line therapy for CML and also the second-generation Bcr-Abl inhibitor nilotinib and the dual BcrAbl/Src inhibitor dasatinib are now successfully used. Ponatinib, AP24534, by Ariad Pharmaceuticals Inc. has been approved by FDA for the treatment of resistant or imatinib-intolerant CML and Ph+ ALL patients, especially those harboring the T315I mutation. On September 2012, bosutinib received the approval by FDA and in 2013 it was approved also by European Medical Agency.

The search for Bcr-Abl inhibitors is very active. Bcr-Abl inhibitors constitute a very appealing research field that can be expected to expand further.

References:

1. Soverini S, et al. Cancer. 2014 Apr 1;120(7):1002-9.

2. Thomas X, et al. Expert Opin Drug Discov. 2016 Nov;11(11):1061-1070.

3. Boer JM, et al. Eur J Cancer. 2017 Sep;82:203-218.

4. Shami PJ, et al. Leukemia. 2012 Feb;26(2):214-24.

5. Wylie AA,et al. Nature. 2017 Mar 30;543(7647):733-737.

Cat. No.	Product Name	Information
PC-20215	PF-114 Bcr-Abl inhibitor	Vamotinib (PF-114) is a potent, selective and orally available inhibitor of native (IC50=0.49 nM) and mutated BCR/ABL (IC50=0.7-4 nM, ABL (T315I) IC50=0.78 nM).
PC-38393	Flumbatinib BCR-ABL inhibitor	Flumatinib (HH-GV678) is a potent BCR-ABL/PDGFR/KIT inhibitor, potently inhibits ABL, PDGFR-β and KIT kinase with IC50 of 1.2, 307.6 and 665.5 nM, respectively.
PC-38379	Vodobatinib BCR-ABL1 inhibitor	Vodobatinib (K0706) is a potent, selective inhibitor of BCR-ABL1 with IC50 of 7 nM (wt BCR-ABL1), exhibits activity against most clinically important BCR-ABL1 point mutants (M244V, IC50=22 nM).
PC-38306	Olverembatinib	Olverembatinib (HQP1351, GZD824) is an orally bioavailable multikinase inhibitor targeting a broad spectrum of mutant KIT kinases (KIT-V559D IC50=1.4 nM).
PC-38025	Radotinib BCR-ABL1 inhibitor	Radotinib (IY-5511) is a potent and selective BCR-ABL1 tyrosine kinase inhibitor with IC50 of 34 nM for wild-type BCR-ABL1 kinase..
PC-43444	WP1130	WP1130 (Degrasyn) is a small molecule that specifically and rapidly down-regulates both wild-type and mutant Bcr/Abl protein without affecting bcr/abl gene expression (IC50=1.8 uM), also inhibits deubiquitinases and blocks autophagy.
PC-62147	Asciminib ABL1 inhibitor	Asciminib (ABL-001) is a potent and selective allosteric ABL1 inhibitor with IC50 of 0.25 nM in BCR–ABL1-transformed BaF3 cells.
PC-60538	CZC-8004	CZC-8004 (CZC8004, Dianilinopyrimidine-01) is a pan-specific kinase inhibitor that binds to a broad range of tyrosine kinases, including ABL, BTK, FAK, FER, JAK1, SRC, SYK, TEC, TNK1, TYK2, and YES at low micromolar concentrations..
PC-45914	Imatinib mesylate	Imatinib mesylate (CGP-57148B, STI-571) is a n orally bioavailability mesylate salt of Imatinib, which is a multi-kinase inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 uM, 0.1 uM and 0.1 uM in cell-free or cell-based assays.
PC-44438	Imatinib	Imatinib (STI571) is a multi-kinase inhibitor of v-Abl, c-Kit and PDGFR with IC50 of 0.6 uM, 0.1 uM and 0.1 uM in cell-free or cell-based assays.
PC-42407	Nilotinib BCR-ABL1 inhibitor	Nilotinib (AMN-107) is a potent, selective, orally available inhibitor of both native and mutant Bcr-Abl with IC50 of 20-80 nM.
PC-42426	Dasatinib Src/Abl inhibitor	Dasatinib (BMS-354825) is a potent, orally bioavailable, dual Src/Abl kinase inhibitor with IC50 of 0.5, 0.4, 0.5 and <1 nM for Src, Lck, Yes and Bcr-Abl, respectively.

PREV12 3 NEXT

Select Your Country or Region

Request The Product List ofBcr-Abl Bcr-Abl

Request The Product List

* Indicates a Required FieldYour information is safe with us.